share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中进医疗 | 6-K:外国发行人报告
美股SEC公告 ·  2024/05/14 13:18

Moomoo AI 已提取核心信息

Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.
Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.
Jin Medical International Ltd.在提交2023财年的年度报告后,成功恢复了对纳斯达克定期申报要求的遵守。该公司此前曾于2024年3月28日收到纳斯达克的通知,称必须在2024年5月20日之前提交报告以维持其上市。该年度报告于2024年4月26日提交,2024年5月9日,纳斯达克确认了该公司的合规性。但是,纳斯达克将在2025年5月9日之前继续监督Jin Medical International对申报规则的遵守情况,在此期间的任何违规行为都将直接导致退市决定,该公司没有机会提交新的合规计划。
Jin Medical International Ltd.在提交2023财年的年度报告后,成功恢复了对纳斯达克定期申报要求的遵守。该公司此前曾于2024年3月28日收到纳斯达克的通知,称必须在2024年5月20日之前提交报告以维持其上市。该年度报告于2024年4月26日提交,2024年5月9日,纳斯达克确认了该公司的合规性。但是,纳斯达克将在2025年5月9日之前继续监督Jin Medical International对申报规则的遵守情况,在此期间的任何违规行为都将直接导致退市决定,该公司没有机会提交新的合规计划。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息